What if your immune data could predict vaccine efficacy?

ImmunoSig helps vaccine and biologics developers answer this using custom peptide and protein microarrays combined with AI and machine learning. We don't just identify immunogenic antigens,we correlate immune profiles with functional protection to guide rational formulation decisions.

The Challenge:
Developing multi-component vaccines with limited samples is guesswork. Traditional methods test 5-10 antigens, require large sample volumes, and can't predict which combinations drive protection. Wrong decisions cost millions and years of development.

Our Solution:
We identify immune fingerprints across hundreds to thousands of targeted antigens from just 20 µL of sample, then correlate them with functional assays (SBA, neutralisation, challenge data) using machine learning. The result: validated predictions of which antigens are worth advancing.

What We Deliver:
✅ Validated correlation between immune profiles and protection
✅ Rationally designed microarrays customized to your vaccine
✅ Minimal sample required - just 20 µL per timepoint
✅ Collaborative interpretation with next-step recommendations
✅ AI-enhanced analysis identifying protective signatures and synergistic combinations

Process: Design → Analysis → Interpretation

Who We Partner With:
Vaccine developers working with limited samples or complex immune questions:
• Multi-component bacterial vaccines (meningococcal, gonococcal, pertussis, TB)
• Whole-cell vaccine characterization
• Antigen prioritization from full proteomes (100-2000+ candidates)

Founded by Scientists:
Our co-founders bring 40+ combined years from the University of Manchester, Finlay Vaccine Institute, GSK-sponsored research, and the Wellcome Trust Gonococcal Vaccine Initiative. We've contributed to licensed vaccines and major vaccine discovery programs.

Ready to Correlate Your Immune Data with Protection?
📧 info@immunosig.com
🌐 www.immunosig.com

Manchester, UK | Research Only

ImmunoSig Ltd.

Org chart

Teams

Offices